Business
Novavax to deliver 60 mln doses of COVID-19 vaccine candidate to UK for trial – The Jakarta Post – Jakarta Post
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.
The trial will be a study in about 9,000 adults between 18 years and 85 years of age.
Novavax would partner…
-
Business21 hours agoWarning! These ASX 200 shares were just downgraded
-
Business14 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News10 hours agoWilliam Robinson dies aged 89
-
General10 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase